Articles |
the Vascular Biology Center (A.P., N.M., J.W.R., J.D.C.), the Department of Pharmacology and Toxicology (A.P., N.M., J.W.R., J.D.C.), the Department of Pathology (A.A., R.G.G.), the Department of Pediatrics (D.H.M.), and the Department of Anesthesiology (J.W.R.), Medical College of Georgia, Augusta, and the Armed Forces Institute of Pathology (R.V., F.D.K.), Washington, DC.
Correspondence to Dr John D. Catravas, Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912-2500.
| Abstract |
|---|
|
|
|---|
and interleukin (IL)-1
, two known secretory products of monocytes, simulated the effects of monocytes on ACE activity. Western blot analysis revealed a decrease in the amount of ACE protein in TNF-
treated and CCCM-treated ECs compared with control ECs. Both TNF-
and IL-1
were present in CCCM and MCM but not EC-conditioned medium. Incubation of the cocultures with a mixture of neutralizing antibodies against TNF-
and IL-1 totally abolished the monocyte-induced decrease in ACE activity. In conclusion, monocytes decrease ACE activity in cultured ECs through the release of cytokines such as TNF-
and IL-1.
Key Words: angiotensin-converting enzyme 5'-nucleotidase surface peptidase tumor necrosis factor-
interleukin-1
| Introduction |
|---|
|
|
|---|
and IL-1 are monocyte/macrophage-derived cytokines with pleiotropic actions on the morphology and biochemistry of various cell types.2 3 4 Endothelium exposed to TNF-
or IL-1 displays increased expression of adhesion molecules, including P-selectin and intercellular adhesion molecule-1.3 4 Moreover, TNF-
and IL-1 stimulate the secretion of other cytokines, such as IL-6, IL-8, and monocyte chemoattractant protein, as well as growth factors, including MCSF, granulocyte-MCSF, and platelet-derived growth factor.2 5 6 Moreover, TNF-
and IL-1 enhance the production of plasminogen activator inhibitor-1, von Willebrand factor, and prostacyclin.6 ACE, AmN, and NCT are ectoenzymes located on the cell surface, each with its catalytic domain facing the extracellular space. It has been postulated that surface peptidases may participate in the regulation of cell growth and differentiation by changing local concentrations of peptide hormones and growth factors.8 ACE, a target enzyme for a novel class of antihypertensive agents, is found in large amounts on the surface of vascular endothelium, where it catalyzes the conversion of the biologically inactive decapeptide angiotensin I to angiotensin II and converts bradykinin to inactive fragments9 ; AmN is believed to participate in the degradation of angiotensin III and Lys-bradykinin.10 NCT dephosphorylates 5'-AMP to adenosine, a known vasorelaxant and antithrombogenic agent.11 12 Angiotensin II is a potent vasoconstrictor that induces smooth muscle migration and proliferation,13 14 whereas the vasodilator bradykinin increases vascular permeability and is believed to be involved in inflammatory processes.15 16
Recent reports have indicated that EC ACE activity is reduced by TNF-
17 and lipopolysaccharide18 and is increased by IL-119 and platelet-activating factor.20 The aim of the present study was to investigate whether interaction of monocytes with ECs alters endothelial ectoenzyme activities. IL-1 and TNF-
have been shown to affect EC receptor expression and coupling to second messenger systems.2 3 An alternative means for monocyte and monocyte-derived cytokine modulation of vasoactive peptide and growth factor action on vascular cells would be alteration of the activity of enzymes involved in peptide formation and degradation. Effects on endothelial ectoenzyme activity could provide a previously unrecognized mechanism for monocyte modulation of cardiovascular homeostasis.
| Materials and Methods |
|---|
|
|
|---|
(2x104 U/mL), and IL-6 (5x106 U/mL) were gifts from Genetics Institute, Cambridge, Mass; TNF-
(3.2x107 U/mL) was a gift from Genentech, San Francisco, Calif. Interferon-
(6x105 U/mL) was purchased from HoffmanLa Roche. The TNF-
and IL-1neutralizing antibodies and the IL-1
immunoassay kit were from R&D Systems; the TNF-
immunoassay kit was purchased from Biosource International. PVDF membrane, dry milk, and Tween 20 were from Bio-Rad Laboratories. The monoclonal antibody 9B9 against ACE21 was from Biotrack, Inc. Matrigel was from Collaborative Research Inc. The ECL system was from Amersham Life Sciences, and the x-ray film was from Eastman Kodak Co. Nonidet P-40, NaCl, aprotinin, phenylmethylsulfonyl fluoride, superoxide dismutase, catalase, Tiron, bovine serum albumin, and dipyridamole were purchased from Sigma Chemical Co. Arg-Phe-[3H]anilide (22 Ci/mmol) and Arg-Pro-Pro-[3H]benzylamide (22 Ci/mmol) were prepared as described previously.22 23
EC and Monocyte Cultures and Cocultures
Primary HAEC cultures were established from thoracic aortas of male victims of sudden traumatic death and were obtained at autopsy within 12 hours of death. HAECs were isolated and cultured as previously described.24 25 Briefly, vessels were separated from connective tissue, cut longitudinally, and washed with Earle's balanced salt solution. ECs were harvested by incubation with 0.15% dispase in medium 199 for 90 to 120 minutes at 37°C. The resulting cell suspensions were pelleted at 600g for 10 minutes and resuspended in growth medium (medium 199 supplemented with 15% FCS, 25 mmol/L HEPES, 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 100 U/mL penicillin, 100 µg/mL streptomycin, 50 µg/mL endothelial cell growth factor, and 30 µg/mL heparin). ECs were seeded at a density of 5 to 8x104 cells/cm2 in plastic flasks previously coated with 0.2% gelatin and were subcultured (1:3) using trypsin. Experiments were performed using confluent ECs (4 to 7 days in culture, passages 2 to 5) from nine different primary cell lines. Purity of cultures and EC identification were assessed by phase microscopy, visualization of Weibel-Palade bodies, presence of von Willebrand factor, and uptake of acetylated low-density lipoprotein.24 26 27 Growth characteristics of ECs under these conditions have been reported previously.26 HUVEC cultures were prepared according to Gimbrone et al28 with minor modifications, using dispase instead of collagenase,26 and were cultured identically to HAECs. PAECs were isolated by incubation with 0.15% dispase for 15 minutes at 37°C. The growth medium used was DMEM, with the same additions used for human ECs but without endothelial cell growth factor. HUVECs and PAECs were used at passages 2 to 5 and 2 to 12, respectively. Smooth muscle cells from porcine aorta were isolated by incubation of vessels with 0.2% collagenase in DMEM for 3 hours and cultured in growth medium (DMEM) with 10% FCS.
Human and porcine monocytes were isolated by counterflow centrifugal elutriation29 from mononuclear cell layers prepared by centrifugation of heparinized blood (500 g, 40 minutes at 18°C) on Ficoll-Paque (d 1.077). Cells were diluted (5 to 20x106 cells per tube) in FCS containing 10% dimethyl sulfoxide, frozen, and stored in liquid nitrogen. The purity of monocyte fractions determined by differential counting of cytospin preparations stained with Villanueva stain (porcine) or monocyte antibody (human) was >95%.
Frozen monocytes were thawed, resuspended in 50 mL of serum-free medium, centrifuged for 10 minutes at 400g, and resuspended in the growth medium used for culturing human or porcine ECs. Confluent EC monolayers cultured in 24-well plates were washed three times with 2 mL of medium 199 (37°C); then growth medium supplemented with 200 U/mL MCSF was added. Monocytes (2 to 50x104 in a final volume of 0.5 mL per well) were added directly to the EC monolayers or to gelatin-coated wells without endothelium. Agents to be tested were added at time 0. After 2 hours of incubation, nonadherent cells (monocytes) were removed from wells by washing three times with medium 199. Agents were resupplied, and cocultures, control ECs, or monocytes were cultured in growth medium with 200 U/mL of MCSF for 48 to 120 hours. The numbers of adherent monocytes were determined by flow cytometry of trypsinized monocyte/EC suspensions stained with HAM 56 or were determined directly in the culture dish using computerized image analysis of HAM 56stained cultures. Monocyte adherence differed with the monocyte and EC donor used, ranging from 15 to 30 monocytes per 100 endothelial cells. To determine whether alteration in endothelial ectoenzyme activity was dependent upon direct contact between monocytes and ECs or the secretion of soluble products by monocytes or endothelium, experiments with both CM and transwell plates were carried out. CM was collected from confluent ECs, monocytes (5x105 per well), or monocyte/EC cocultures. CM from all three sources was collected after 24 hours (day 0) and on days 4, 9, and 12. In the case of cocultures and monocytes alone, nonadherent cells were removed after 24 hours. Fresh growth medium was added after each collection. The CM were centrifuged for 10 minutes at 400g, filtered through 0.22-µm filters, and stored at -20°C if not immediately used. To analyze CM for their abilities to decrease ACE activity with parallel assay for the presence of TNF-
and IL-1
, CM were pooled from four to six 2-cm2 wells. Cytokine concentrations were determined in triplicate. CM effects on ACE activity were measured in quadruplicate. The transwells (diameter, 6.5 mm; distance from the bottom, 1.5 mm) were coated with matrigel, rinsed three times with medium 199, and then inserted into 24-well plates containing confluent EC cultures. Monocytes (2x105 cells per well) were either added into transwells or directly onto ECs, and ACE activity was estimated 48 hours later. Migration of monocytes across transwell membranes coated with matrigel was not observed. To visualize EC borders, cultures were fixed for 10 minutes with 3.7% paraformaldehyde, stained with 0.2% silver nitrate,30 and counterstained with pararosaniline.
EC Ectoenzyme Activity Assays
EC ACE, AmN, AmP, and NCT assays were performed in separate 2-cm2 wells under first-order reaction conditions. Confluent control- or cytokine-treated ECs or cocultures of ECs with monocytes were incubated with the appropriate substrate for 30 minutes (ACE, AmN, and NCT) for HUVECs and HAECs and for 60 minutes for PAECs. Incubation time was 4 hours for AmP activity measurements for both porcine and human cells. After two gentle washes with Earle's salt solution to remove traces of serum, cytokines, and other chemical treatments, enzymatic reactions were carried out at 37°C in a final volume of 0.6 mL Earle's salt solution. The substrates used were [3H]benzoyl-Phe-Ala-Pro (0.2 µCi/mL) for ACE,31 Arg-Phe-[3H]anilide (0.2 µCi/mL) for AmN,23 Arg-Pro-Pro-[3H]benzylamide (0.2 µCi/mL) for AmP,22 and [14C]5'-AMP (50 nCi/mL, 53.8 mCi/mmol) for NCT. Dipyridamole (0.1 mmol/L) was included in the last reaction mixture to prevent the cellular uptake of [14C]adenosine, the 14C-labeled product formed by NCT. Reactions were stopped by either placing the plate into an ice bath or by removing samples into acid or base.
For the peptidase activity assays, radiolabeled products ([3H]benzoyl-Phe, Phe-[3H]anilide, and Pro-Pro-[3H]benzylamide for ACE, AmN, and AmP, respectively) were separated from parent compounds by extraction into toluene. An aliquot from each supernatant was transferred to a 7-mL polyethylene scintillation vial containing 5 mL of scintillation cocktail (Ecoscint A). Total 3H radioactivity was measured in a Beckman LS7500 liquid scintillation spectrometer (Beckman Instruments). [3H]Benzoyl-Phe was separated from unreacted substrate by transferring 0.1-mL aliquots, in duplicate, to 7-mL scintillation vials containing 2.9 mL of 0.12N HCl, to which 3 mL of toluene supplemented with 4 g/L omnifluor was added. For the extractions of Phe-[3H]anilide and Pro-Pro-[3H]benzylamide, 0.2-mL aliquots were added to 0.2 mL of 0.2N NaOH. To that, 3 mL of Ventrex cocktail No. 1 (a toluene-based cocktail) was added. Products were preferentially extracted into the organic phase, and radioactivity was determined by liquid scintillation spectrometry after storing the samples overnight (AmN and AmP) or for 48 hours (ACE) in the dark. Since a small amount (5% to 15%) of the parent compounds was also extracted into toluene, correction for this extraction was undertaken as previously described.32 [14C]Adenosine was separated from [14C]AMP on a disposable anion-exchange column. Three 0.3-mL aliquots were transferred into 7-mL polyethylene scintillation vials, each containing 6 mL of scintillation cocktail (Ecoscint A), and total 14C activity was measured. Duplicate 0.3-mL aliquots were transferred to disposable chromatography columns containing 2.1 mL of Dowex 1x8 400-mesh (Cl-) anion-exchange resin retained on a glass wool plug. The columns bind [14C]5'-AMP, whereas [14C]adenosine is eluted with 3 mL of 1 mmol/L NaCl in 20% ethanol. Radioactivity was measured in 6 mL Ecoscint A. In this way, 70% of the dephosphorylated compound (ie, [14C]adenosine) was eluted, whereas <5% of the parent ([14C]5'-AMP) appeared in the eluent.
Enzyme activity was calculated as follows:
![]() |
Protein Measurements
Protein content of the supernatant of the centrifuged (2000 rpm for 5 minutes at room temperature) NaOH-solubilized samples was measured by the Bradford method.34 Bovine albumin in NaOH was used as the standard. To determine the protein concentration of samples that were used for Western blotting, the standard curve was constructed in appropriate buffer.
Immunoblotting
Cells were cultured in 100-mm-diameter dishes, incubated with vehicle, TNF-
(1000 U/mL, 4x105 monocytes/mL), or day 0 CCCM for 48 hours, and then lysed in lysis buffer (20 mmol/L HEPES/NaOH buffer, pH 7.0, containing 1% Nonidet P-40, 150 mmol/L NaCl, 1 mmol/L EDTA, 10 µg/mL aprotinin, and 1 mmol/L phenylmethylsulfonyl fluoride). Cell lysates were centrifuged at 20 000 rpm, the supernatant fraction was collected, and protein concentration was measured. Samples (50 µg of protein per lane) were electrophoresed in a 4% to 20% gradient polyacrylamide gel and transferred to a PVDF membrane at 60 V for 3 hours at 4°C in a buffer containing 25 mmol/L Tris and 700 mmol/L glycine. Membranes were then incubated overnight at 4°C with 5% dry milk in buffer containing 0.1% (vol/vol) Tween 20 in Tris-buffered solution (TTBS) to block nonspecific binding. The following day, membranes were incubated with a monoclonal antibody for ACE in 1% milk in TTBS, washed three times with TTBS for 20 minutes each time, blocked for an additional hour with 5% milk in TTBS, and finally incubated for 1 hour with a horseradish peroxidaseconjugated anti-mouse IgG. Immunoreactive protein bands were visualized using the ECL system after 10 minutes of exposure to x-ray film. To check for equality in loading and transfer, membranes were subsequently incubated with a monoclonal antibody against tubulin, and immunoreactive bands were visualized after exposure to x-ray film for 30 seconds.
Data Analysis
Data are presented as mean±SEM of the indicated number of individual cultures. Enzyme activity data are expressed as percentage of the control EC value. Statistical comparisons between groups were performed using ANOVA or Student's t test, as appropriate. Differences among means were considered significant when P<.05.
| Results |
|---|
|
|
|---|
|
Ectoenzyme Activities in EC-Monocyte Cocultures
Cultured HAECs, HUVECs, and PAECs expressed ACE (0.88±0.03, 6.17±0.23, and 0.32±0.01 U per monolayer), AmN (0.49±0.03, 0.63±0.01, and 0.17±0.02 U per monolayer), and NCT (3.81±0.18, 5.83±0.26, and 0.41±0.01 U per monolayer) activities, respectively. AmP activity was 2.02±0.1x10-2 and 0.2±0.01x10-2 U per monolayer for HAECs and PAECs, respectively. Human monocytes when cultured on plastic displayed smaller activities for ACE, AmN, and NCT than did ECs. No AmP activity was detected in human monocytes. Porcine monocytes on the other hand exhibited eightfold higher NCT activity, similar AmN activity, and 60% of the ACE activity compared with PAECs. Coculture of HAECs and HUVECs with freshly isolated human monocytes for 2 to 4 days led to a decrease in ACE activity (to 64.5±3.5% and 59.4±1.1% of control values in HAEC and HUVEC monocyte cocultures) without affecting NCT and AmN activities (Fig 2A and 2B![]()
). AmP activity was not different in HAEC and HAEC-monocyte cocultures (2.02±0.1x10-2 and 2.05±0.1x10-2 U per monolayer, respectively). Similar results were obtained when activities were expressed per cell number or per milligram protein. Protein content per monolayer remained unaltered upon cocultivation of ECs with monocytes (75.9±2.1 and 72.7±2.9 µg per monolayer) for HAEC and HAEC-monocyte cocultures, respectively. Similarly, EC cell number per monolayer was not different in EC and EC-monocyte cocultures (150 000 per monolayer). ACE activity was also diminished in PAEC and porcine-monocyte cocultures (to 56.7±5.3% of control values, Fig 2C
), whereas AmP was found to be unaltered, and NCT and AmN activities were increased in cocultures compared with ECs, probably because of the high NCT and AmN activities of monocytes.
|
The remainder of the studies focused on the mechanism of monocyte-mediated reduction in endothelial ACE activity. Since porcine and human ECs showed similar diminishment in ACE activity upon coculture with monocytes, the three different EC types were used interchangeably. ACE activity in PAEC-monocyte cocultures (2x105 monocytes and 2x105 ECs per coculture) decreased in a time-dependent manner, reaching significance at 48 hours. After 120 hours, monocyte-induced decline in ACE activity reached a maximum, with only 30.4±4.0% and 34.8±3.0% of control ACE activity remaining in the presence or absence of MCSF. Addition of MCSF (200 U/mL) did not affect EC ACE activity, nor did it alter the time course of decline in ACE activity in the presence of monocytes (Fig 3A
). The decrease in ACE activity was also monocyte-number dependent (Fig 3B
). A plateau in the monocyte-mediated decrease in ACE activity was observed at 2x105 monocytes per well. Addition of MCSF potentiated the decrease in ACE activity at low monocyte concentrations (2x104). Experiments were performed using both freshly isolated and freeze-thawed monocytes and yielded similar results. Subsequent experiments were thus performed with freeze-thawed monocytes.
|
We investigated whether the decrease in cell-associated PAEC ACE activity was due to monocyte protease action, releasing ACE into the culture medium. Cells were incubated with media containing 2% heat-inactivated FCS for 48 hours. The CM was collected and then centrifuged at 1000 rpm for 10 minutes to remove floating cells. Medium ACE activities from control EC and EC-monocyte cocultures were not significantly different (Table 1
). Moreover, monocyte-induced free radical production was not found to be involved in the decrease in ACE activity. Addition of extracellular (300 U/mL superoxide dismutase or 2000 U/mL catalase) or intracellular (10 mmol/L Tiron or 5 mmol/L dimethylthiourea) free radical scavengers in the cocultures for the entire 48 hours did not protect against the decrease in ACE activity (Fig 4
). Cell-cell contact between monocytes and ECs was not essential for the monocyte-mediated decrease in ACE activity, since CCCM and physical separation of monocytes in the cocultures by cultivation of monocytes in transwells yielded similar decreases in ACE activity (Table
s 1 and 2). Freezing and thawing the CCCM did not result in loss of the medium's ability to decrease ACE activity (Table 2
). To investigate whether monocytes also induced a decrease in smooth muscle ACE activity, ACE activity was determined in porcine aortic smooth musclemonocyte cocultures. In both the presence and absence of MCSF, no alteration in ACE activity was observed (111.4±4.9% versus 108.6±7.8% of control smooth muscle cell ACE activity values for the +MCSF and -MCSF groups, respectively).
|
|
|
Effects of Exogenously Added Cytokines on Ectoenzyme Activities
To further characterize the soluble factor(s) responsible for the decrease in ACE activity in the cocultures, we tested for effects of several monocyte-derived cytokines on ACE and NCT activities (Fig 5
). Incubation of HAECs with 1000 U/mL TNF-
for 48 hours decreased ACE activity to 63.3±4.4% of control without affecting NCT activity. Added TNF-
induced morphological changes of ECs similar to those produced by monocytes. Similar results, though less pronounced, were obtained by adding 50 U/mL IL-1
. IL-6 (1000 U/mL) had no effect on either ACE or NCT activities. IFN-
(1000 U/mL) did not affect ACE but increased NCT activity. TNF-
also induced a decrease in HUVEC ACE activity. This decrease was time and concentration dependent (Fig 6
). Moreover, a combination of 100 U/mL TNF-
and 50 U/mL IL-1
had a greater effect on ACE activity than either cytokine alone (Fig 7
).
|
|
|
TNF-
and IL-1 in CM
No TNF-
or IL-1
was present in measurable amounts in EC CM (Table 3
). TNF-
was present only in day-0 MCM and CCCM. IL-1
secretion was more sustained than TNF-
secretion, remaining detectable even in day-9 CCCM and MCM. MCM exhibited higher concentrations of TNF-
and IL-1
and greater inhibition of EC ACE activity compared with CCCM. TNF-
was measured in concentrations sufficient by itself to account for the decrease in EC ACE activity. IL-1
was present in lower concentrations (20% of that added exogenously) and may have contributed to decreases in ACE activity by acting additively with TNF-
(Table 3
, Fig 7
).
|
Effects of AntiTNF-
and AntiIL-1Neutralizing Antibodies on Monocyte-Induced Downregulation of ACE Activity
An antiTNF-
neutralizing antibody was used in HUVEC-monocyte cocultures to investigate whether neutralization of TNF-
released in the coculture medium could prevent the monocyte-induced decrease in ACE activity (Fig 8
). The ability of exogenously added TNF-
to depress EC ACE activity was fully antagonized by the antiTNF-
neutralizing antibody (2 µg/mL). The antiTNF-
antibody did not itself affect EC ACE activity. In cocultures, the antiTNF-
neutralizing antibody inhibited the monocyte-induced decrease in ACE activity by 25%, suggesting that TNF-
is responsible, at least in part, for the monocyte-induced decrease in ACE activity (Fig 8
). No additional protective effect of the antibody was observed when its concentration was doubled (4 µg/mL), as ACE activity remained at 67% of control. In HAEC-monocyte cocultures (Fig 9
), a neutralizing antibody against IL-1
was ineffective in preventing the reduction in ACE activity. Neither of the antibodies, when added alone, had any effect on EC ACE activity. Combination of the neutralizing antibodies against TNF-
and IL-1 fully prevented the reduction in ACE activity.
|
|
Immunoblotting
Western blot analysis of total cell lysates revealed a 170-kD band for ACE (Fig 10
). ACE protein levels were found to be decreased in HAEC-monocyte cocultures and in HAEC cultures treated with CCCM or TNF-
.
|
| Discussion |
|---|
|
|
|---|
or IL-1
conferred effects similar to those of monocytes on ACE activity. (6) Culture supernatants from monocytes and EC-monocyte cocultures, but not ECs, contained TNF-
and IL-1
in concentrations sufficient to decrease EC ACE activity. (7) Incubation of the EC-monocyte cocultures with a mixture of neutralizing antibodies against TNF-
and IL-1 fully prevented the monocyte-induced decrease in ACE activity. (8) Reduction in EC ACE activity by monocytes and TNF-
resulted from decreased levels of ACE protein.
Porcine monocytes displayed severalfold higher NCT and AmN activities comparable to PAECs (Fig 2C
). As enzyme activity determined in the cocultures is the sum of the activities present on the endothelium and the monocytes, the observation that NCT and AmN activities are greater in porcine cocultures than in EC monolayers is not surprising. If one compares the combined AmN activity of ECs and monocytes to that of EC-monocyte cocultures, the latter exhibit a depressed enzyme activity (Fig 2A and 2B![]()
). Such comparisons, however, may be inappropriate since (1) the exact number of monocytes in the cocultures or when cultured alone was not determined in the present study and (2) there is a difference in the phenotype between monocytes cultured on plastic and those cultured on ECs.37
On the basis of data obtained from the time course and monocyte concentration experiments, a 48-hour coculture period was used with 4x105 monocytes/mL, a concentration well within the range of monocytes in blood (4.6x105 monocytes/mL38 ). MCSF is a cytokine affecting survival, proliferation, and differentiation of hemopoietic progenitor cells into monocytes; it also regulates some mature cell functions.39 40 Addition of MCSF to the cocultures did not change the time course of the monocyte effects, but it increased the action of monocytes at low monocyte concentrations. Augmentation of the monocyte effects by MCSF may be explained by an increased survival rate and/or stimulation of cytokine production by monocytes. Even though MCSF is constitutively expressed by both endothelial41 and smooth muscle cells,42 we routinely included 200 U/mL MCSF in experiments involving monocytes to ensure constant MCSF levels.
Smooth muscle cells possess ACE activity.43 44 Effects of monocytes on ACE activity were found to be endothelium selective, since smooth muscle ACE activity was not significantly reduced in the presence of monocytes. Monocytes express and release proteinases.45 46 It is nonetheless unlikely that the decreased EC-associated ACE activity was the result of proteolytic cleavage of the membrane-bound ACE, since EC and EC-monocyte CCCM exhibited similar ACE activities.
Monocytes produce free radicals under certain conditions.36 47 48 49 Enzymatically generated superoxide anion (O2-) by the xanthinexanthine oxidase reaction or addition of exogenous hydrogen peroxide decreases ACE activity in cultured bovine pulmonary artery ECs.35 Free radical scavengers protect against the decline in EC ACE activity caused by phorbol myristate acetateactivated neutrophils.35 However, free radicals appear not to be involved in the monocyte-induced decrease in ACE activity described here. Both superoxide dismutase, an extracellular O2- scavenger, and Tiron, an agent that scavenges O2- both extracellularly and intracellularly, failed to protect the monocyte-mediated decrease in ACE activity. Moreover, catalase and dimethylthiourea, scavengers of hydrogen peroxide and hydroxyl radicals, respectively, were not effective in preventing the decrease in ACE activity induced by monocytes.
The increased ACE activity observed in control PAECs (Table 1
) between days 2 and 5 is in agreement with previous reports indicating that ACE activity increases after confluence.50 51 Although certain actions of monocytes on ECs require cell-cell contact, other actions are mediated by soluble factors.7 52 CM from either monocytes or EC-monocyte cocultures added to EC monolayers for 2 or 5 days decreased EC ACE activity to an extent comparable to that observed in EC-monocyte cocultures. Similar results were obtained with monocytes cultured in transwells, thus preventing direct cell-cell contact between the two cell types. A possible soluble factor(s) mediating the decrease in ACE activity includes the monocyte secretory products IL-1 and TNF-
. In the present study, TNF-
reduced endothelial ACE activity in a time- and concentration-dependent manner. This observation is in agreement with Hennig et al,17 who reported that exposure of porcine EC to TNF-
lowered ACE activity. Matucci-Cerinic et al,19 however, have reported that HUVEC ACE activity increases after exposure to IL-1
; IL-1
has been reported by others to mimic practically every action of TNF-
on cultured ECs.2 In the present study, IL-1
suppressed ACE activity (Fig 7
). It is interesting to note that systemic administration of TNF-
or IL-1 results in hypotension, which is at least partly due to increased NO formation through induction of NO synthase in the vascular wall.3 4 53 54 A reduction in ACE activity with a consequent decrease in circulating angiotensin II levels could contribute to the hypotensive effect of these cytokines.
Exposure of ECs to TNF-
can reduce intracellular zinc concentration as well as the activities of zinc-dependent enzymes, such as ACE.17 Reduced catalytic activity does not appear to be the mechanism of TNF-
and monocyte-mediated decrease in ACE activity, since in Western blot analysis the 170-kD band for ACE was decreased in HAEC-monocyte cocultures as well as in HAECs treated with TNF-
or CCCM. Further studies are required to determine whether the decreased levels of ACE protein are due to decreased synthesis or increased degradation of protein and/or mRNA.
Cultured monocytes can release cytokines into the growth medium even in the absence of pharmacological stimulation.55 56 On the other hand, ECs do not constitutively express IL-1 and TNF-
but have been shown to do so upon activation with various cytokines.3 4 In the present study, EC CM did not contain detectable amounts of immunoreactive cytokines. However, day-0 CCCM and MCM contained TNF-
, with the latter containing fivefold more TNF-
and inhibiting ACE activity to a greater extent than CCCM. TNF-
concentrations in both MCM and CCCM fell to undetectable levels after day 0. IL-1
was detectable in both MCM and CCCM even after prolonged cocultivation of EC with monocytes. To investigate the role of TNF-
in the effects of monocytes on ACE activity, a TNF-
neutralizing antibody was used. The TNF-
neutralizing antibody completely inhibited the action of exogenously added TNF-
. The same antibody partially prevented the effects of monocytes on EC ACE activity, suggesting that TNF-
is one of the cytokines involved in the downregulation of ACE activity. In addition, incubation of the cocultures with a neutralizing antibody against IL-1ß partially prevented the effects of monocytes. A mixture of neutralizing antibodies against TNF-
and IL-1 restored ACE activity, suggesting that the monocyte-induced reduction in ACE activity is mediated by the release of these cytokines.
Cocultivation of monocytes with ECs has also been shown to augment the production of prostacyclin (PGI2), von Willebrand factor, and type I plasminogen activator inhibitor by ECs.7 Parallel experiments performed in our laboratory showed larger amounts of EDNO released by either PAECs or HAECs than by PAEC- or HAEC-monocyte cocultures.57 The reduction in EDNO release in the cocultures was first observed at 6 hours, whereas the decrease in ACE activity was not evident until 48 hours. It should be stressed that the effects of monocytes on EC morphology and biochemistry (EDNO, ACE) did not require the addition of a monocyte activator, such as endotoxin.58 Hahn et al58 recently reported that incubation of human peripheral monocytes with concentrations of angiotensin II close to those found in blood leads to increased production of TNF-
as well as increased adherence of monocytes to HUVECs. All of the aforementioned effects of monocytes on EDNO, PGI2, von Willebrand factor, and type I plasminogen activator inhibitor were manifest within 24 hours. It is possible that the early effects (<24 hours) of monocytes on EC phenotype contribute to increased recruitment of monocytes and increased adherence of monocytes and other blood elements to the EC surface. On the other hand, the later observed inhibition of ACE activity by monocytes may represent a negative-feedback mechanism, limiting monocyte activation and adherence to ECs.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received August 9, 1995; accepted June 13, 1996.
| References |
|---|
|
|
|---|
2.
Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev. 1990;70:427-451.
3.
Vilcek J, Lee TH. Tumor necrosis factor. J Biol Chem. 1991;266:7313-7316.
4.
Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627-1652.
5. Pober JS, Lapierre LA, Stolpen AH, Brock TA, Springer TA, Fiers W, Bevilacqua MP, Mendrick DL, Gimbrone MA Jr. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin-1 species. J Immunol. 1987;138:3319-3324.[Abstract]
6.
Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science. 1989;243:1160-1165.
7. Hakkert BC, Rentenaar JM, Van Mourik JA. Monocytes enhance endothelial von Willebrand factor release and prostacyclin production with different kinetics and dependency on intercellular contact between these two cell types. Br J Haematol. 1992;80:495-503.[Medline] [Order article via Infotrieve]
8. Kenny AJ, O'Hare MJ, Gusterson BA. Cell-surface peptidases as modulators of growth and differentiation. Lancet. 1989:785-787.
9.
Dorer FE, Kahn JR, Lentz KE, Levine M, Skeggs LT. Hydrolysis of bradykinin by angiotensin converting enzyme. Circ Res. 1974;34:824-827.
10.
Ryan JW. Peptidase enzymes of the pulmonary vascular surface. Am J Physiol. 1989;257:L53-L60.
11. Arch JRS, Newsholme EA. The control of the metabolism and the hormonal role of adenosine. Essays Biochem. 1978;14:82-123.[Medline] [Order article via Infotrieve]
12. Ryan JW, Smith US. Metabolism of adenosine 5' monophosphate during circulation throughout the lungs. Trans Assoc Am Physicians. 1971;84:297-306.[Medline] [Order article via Infotrieve]
13. Heagerty AM. Angiotensin II: vasoconstrictor or growth factor? J Cardiovasc Pharmacol. 1991;18(suppl 2):S14-S19.
14. Bell I, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990;137:7-12.[Abstract]
15.
Gawlowski DM, Duran WD. Dose related effects of adenosine and bradykinin on microvascular permselectivity to micromolecules in the hamster cheek pouch. Circ Res. 1986;58:348-355.
16. Marceau F, Lussier A, Regoli D, Giroud JP. Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol. 1983;14:209-229.[Medline] [Order article via Infotrieve]
17. Hennig BY, Wang, Ramasamy S, McClain CJ. Zinc protects against tumor necrosis factor-induced disruption of porcine endothelial cell monolayer. J Nutr. 1993;123:1003-1009.
18. Watanabe K, Lam G, Keresztes RS, Jaffe EA. Lipopolysaccharides decrease angiotensin converting enzyme activity expressed by cultured human endothelial cells. J Cell Physiol. 1992;150:433-439.[Medline] [Order article via Infotrieve]
19. Matucci-Cerinic M, Jaffa A, Kahaleh B. Angiotensin converting enzyme: an in vivo and in vitro marker of endothelial injury. J Lab Clin Med. 1992;120:428-433.[Medline] [Order article via Infotrieve]
20. Kawaguchi H, Sawa H, Iizuka K, Yasuda H. Platelet-activating factor stimulates angiotensin converting enzyme activity. J Hypertens. 1990;8:173-177.[Medline] [Order article via Infotrieve]
21. Danilov SM, Faerman AI, Printseva OY, Martynov AV, Sakharov IY, Trakht IN. Immunohistochemical study of angiotensin converting enzyme in human tissues using monoclonal antibodies. Histochemistry. 1987;87:487-490.[Medline] [Order article via Infotrieve]
22. Ryan JW, Chung AYK, Berryer P, Sheffy DH. A radioassay for aminoacylproline hydrolase (aminopeptidase P) activity. Biochem Biophys Acta. 1992;1119:133-139.[Medline] [Order article via Infotrieve]
23. Ryan JW, Chung AYK, Nearing JA, Valido FA, Shun-Cun C, Berryer P. A radiochemical assay for aminopeptidase N. Anal Biochem. 1992;1119:133-139.
24. Antonov AS, Nikolaeva MA, Klueva TS, Romanov YA, Babaev VR, Bystrevskaya VB, Perov NA, Repin VS, Smirnov VN. Primary culture of endothelial cells from atherosclerotic human aorta, I: identification, morphological and ultrastructural characteristics of two endothelial subpopulations. Atherosclerosis. 1986;59:1-19.[Medline] [Order article via Infotrieve]
25.
Antonov AS, Lukashev ME, Romanov YA, Tkachuk VA, Repin V, Smirnov VN. Morphological alterations in endothelial cells from human aorta and umbilical vein induced by forskolin and phorbol esters PMA: a synergistic action of adenylate cyclase and protein kinase C activators. Proc Natl Acad Sci U S A. 1986;83:9704-9708.
26.
Farber HW, Antonov AS, Romanov YA, Smirnov VN, Scarfo LM, Beer DJ. Cytokine secretion by human aortic endothelial cells is related to degree of atherosclerosis. Am J Physiol. 1992;262:H1088-H1095.
27. Antonov AS, Key NS, Smirnov MD, Jacob HS, Vercellotti GM, Smirnov VN. Prothrombotic phenotype diversity of human aortic endothelial cells in culture. Thromb Res. 1992;67:135-145.[Medline] [Order article via Infotrieve]
28.
Gimbrone MA Jr, Cotran RS, Folkman J. Human vascular endothelial cells in culture: growth and DNA synthesis. J Cell Biol. 1974;60:673-689.
29.
Gerrity RG, Goss JA, Soby L. Control of monocyte recruitment by chemotactic factor(s) in lesion-prone areas of swine aorta. Arteriosclerosis. 1985;5:55-56.
30.
Shyrinsky VP, Antonov AS, Birukov KG, Sobolevsky AV, Romanov YA, Kabaeva NV, Antonova GN, Smirnov VN. Prothrombotic phenotype diversity of human aortic endothelial cells in culture. J Cell Biol. 1989;109:331-339.
31. Ryan JW. Assay of peptidase and protease enzymes in vivo. Biochem Pharmacol. 1983;32:2127-2137.[Medline] [Order article via Infotrieve]
32. Catravas JD, Burch SE, Spurlock BO, Mills LR. Early effects of ionizing radiation on pulmonary endothelial angiotensin converting enzyme and 5 nucleotidase, in vivo. Toxicol Appl Pharmacol. 1988;94:342-355.[Medline] [Order article via Infotrieve]
33. Segel IH. Enzyme Kinetics. New York, NY: John Wiley & Sons Inc; 1975.
34. Bradford M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-253.[Medline] [Order article via Infotrieve]
35.
Chen X, Catravas JD. Neutrophil-mediated endothelial angiotensin converting enzyme dysfunction: role of oxygen-derived free radicals. Am J Physiol. 1993;265:L243-L249.
36. Dukes CS, Matthews TJ, Weinberg JB. Human immunodeficiency virus type 1 infection of human monocytes and macrophages does not alter their ability to generate an oxidative burst. J Infect Dis. 1993;168:459-462.[Medline] [Order article via Infotrieve]
37.
Schumann RR, van der Bosch J, Ruller S, Ernst M, Schlaak M. Monocyte long term cultivation on microvascular endothelial cell monolayers: morphologic and phenotypic characterization and comparison with monocytes cultured on tissue culture plastic. Blood. 1989;73:818-826.
38. Diem K, Lentner C. Scientific Tables. Basel, Switzerland: CIBA-Geigy; 1972:619.
39. Nicola NA. Hemopoietic cell growth factors and their receptors. Annu Rev Biochem. 1989;58:45-77.[Medline] [Order article via Infotrieve]
40.
Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood. 1986;67:257-267.
41.
Sieff CA, Niemeyer CM, Mentzer SJ, Faller DV. Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells. Blood. 1988;72:1316-1323.
42. Filonzi EL, Zoellner H, Stanton H, Hamilton JA. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis. 1993;99:241-252.[Medline] [Order article via Infotrieve]
43. Andre P, Schott C, Nehlig H, Stocklet J-C. Aortic smooth muscle cells are able to convert angiotensin I to angiotensin II. Biochem Biophys Res Commun. 1990;173:1137-1142.[Medline] [Order article via Infotrieve]
44. Pipili E, Manolopoulos VG, Catravas JD, Maragoudakis ME. Angiotensin converting enzyme activity is present in the endothelium-denuded aorta. Br J Pharmacol. 1989;98:333-335.[Medline] [Order article via Infotrieve]
45.
Xie DL, Meyers R, Homandberg GA. Release of elastase from monocytes adherent to a fibronectin-gelatin surface. Blood. 1993;81:186-192.
46. Wahl LM, Corcoran ML. Regulation of monocyte/macrophage metalloproteinase production by cytokines. J Periodontol. 1993;64:467-473.[Medline] [Order article via Infotrieve]
47.
Munn DH, Armstrong E. Cytokine regulation of human monocyte differentiation in vitro: the tumor-cytotoxic phenotype induced by macrophage colony-stimulating factor is developmentally regulated by gamma-interferon. Cancer Res. 1993;53:2603-2613.
48.
Jendrossek V, Peters AM, Buth S, Liese J, Wintergerst U, Belohradsky BH, Gahr M. Improvement of superoxide production in monocytes from patients with chronic granulomatous disease by recombinant cytokines. Blood. 1993;81:2131-2136.
49. Tritsch GL, Evans RL. Graphic analysis of superoxide secretion by phagocytic leukocytes at different cell concentrations. J Immunol Methods. 1993;160:59-63.[Medline] [Order article via Infotrieve]
50. Ryan US, Ryan JW. Vital and functional activities of endothelial cells. In: Nossel HL, Vogel HJ, eds. Pathobiology of the Endothelial Cell. New York, NY: Academic Press Inc; 1982:455-469.
51.
Shai S-Y, Fishel RS, Martin BM, Berk BC, Bernstein KE. Bovine angiotensin converting enzyme cDNA cloning and regulation: increased expression during endothelial cell growth arrest. Circ Res. 1992;70:1274-1281.
52.
Zhang H, Downs EC, Lindsey JA, Davis WB, Whisler RL, Cornwell DG. Interactions between the monocyte/macrophage and the vascular smooth muscle cell: stimulation of mitogenesis by a soluble factor and of prostanoid synthesis by cell-cell contact. Arterioscler Thromb. 1993;13:220-230.
53. Beasley D, Schwartz JH, Brenner BM. Interleukin 1 induces prolonged L-arginine dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest. 1991;87:602-608.
54. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett. 1990;275:87-90.[Medline] [Order article via Infotrieve]
55. Bennett S, Por SB, Stanley ER, Breit SN. Monocyte proliferation in a cytokine-free, serum-free system. J Immunol Methods. 1992;153:201-212.[Medline] [Order article via Infotrieve]
56. Burchett SK, Weaver WM, Westall JA, Larsen A, Kronheim S, Wilson CB. Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol. 1988;140:3473-3481.[Abstract]
57. Marczin N, Antonov A, Gerrity RG, Catravas JD. Monocyte adhesion to cultured endothelial cells suppresses the release of biologically active endothelium-derived nitric oxide (NO). Circulation. 1993;88(suppl I, pt 2):I-367. Abstract.
58. Hahn AWA, Jonas U, Buhler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett. 1994;347:178-180.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
M. Flesch, A. Hoper, L. Dell'Italia, K. Evans, R. Bond, R. Peshock, A. Diwan, T. A. Brinsa, C.-C. Wei, N. Sivasubramanian, et al. Activation and Functional Significance of the Renin-Angiotensin System in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor Circulation, August 5, 2003; 108(5): 598 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Itoh, J. Kajikuri, T. Tada, Y. Suzuki, and Y. Mabuchi Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries J. Physiol., May 1, 2003; 548(3): 893 - 906. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Todorov, M. Muller, F. Schweda, and A. Kurtz Tumor necrosis factor-alpha inhibits renin gene expression Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1046 - R1051. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hafizi, J. Wharton, K. Morgan, S. P. Allen, A. H. Chester, J. D. Catravas, J. M. Polak, and M. H. Yacoub Expression of Functional Angiotensin-Converting Enzyme and AT1 Receptors in Cultured Human Cardiac Fibroblasts Circulation, December 8, 1998; 98(23): 2553 - 2559. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |